drugset / Trial / NCT06598943

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943

Phase 2 Recruiting 140 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

Timeline

Start
2024-10-10
Primary completion
2027-12
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrekibart Monoclonal antibody
Subject Mirikizumab Monoclonal antibody

Indications